More Nexalis Therapeutics Limited news
Nexalis Therapeutics LimitedASX: NX1

IRX-616a Study Order Executed to Commence Phase 1

Apr 17, 2025 at 12:08 AM EDT · Issued by Nexalis Therapeutics Limited

Filed with ASX · Apr 17, 2025 at 12:08 AM EDT

On 6ix: 6ix.com/news/irx-616a-study-order-executed-to-commence-phase-1

Nexalis Therapeutics Limited has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Nexalis Therapeutics Limited on 6ix

Story so far

  • Study Order Executed for Phase 2 BTcP TrialMar 13, 2025

Earlier from Nexalis Therapeutics

  • Study Order Executed for Phase 2 BTcP TrialMar 13, 2025
  • Updated Dec24 Quarterly Activities ReportJan 24, 2025
  • Dec24 Quarterly Activities ReportJan 23, 2025
  • Dec24 Appendix 4C Cash Flow ReportJan 23, 2025
  • Shareholder UpdateDec 19, 2024

Later from Nexalis Therapeutics

  • IRX Completes First Drawdown Under Clendon FacilityApr 24, 2025
  • Mar25 Appendix 4C Cash Flow ReportApr 28, 2025
  • Mar25 Quarterly Activities ReportApr 28, 2025
  • Jun25 Appendix 4C Cash Flow ReportJul 22, 2025
  • Jun25 Quarterly Activities ReportJul 22, 2025
All Nexalis Therapeutics news releases↗

Follow Nexalis Therapeutics into a list and get an email when it puts out news.

Follow Nexalis Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer